Corpus overview


MeSH Disease

Human Phenotype

Fever (70)

Pneumonia (66)

Cough (32)

Respiratory distress (22)

Anosmia (17)


    displaying 1 - 10 records in total 1325
    records per page

    Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19

    Authors: Alessandra Vitelli Sr.; Stefania Capone Sr.; Angelo Raggioli; Michela Gentile; Simone Battella; Armin Lahm; Andrea Sommella; Alessandra Maria Contino; Richard A Urbanowicz; Romina Scala; Federica Barra; Adriano Leuzzi; Eleonora Lilli; Giuseppina Miselli; Alessia Noto; Maria Ferraiuolo; Francesco Talotta; Theocharis Tsoleridis; Silvia Meschi; Marco Soriani; Antonella Folgori; Jonathan K Ball; Stefano Colloca

    doi:10.1101/2020.10.22.349951 Date: 2020-10-22 Source: bioRxiv

    The COVID-19 pandemic caused by the emergent SARS-CoV-2 coronavirus threatens global public health and there is an urgent need to develop safe and effective vaccines. Here we report the generation and the preclinical evaluation of a novel replication-defective gorilla adenovirus-vectored vaccine encoding the pre-fusion stabilized Spike (S) protein of SARS-CoV2. We show that our vaccine candidate, GRAd-COV2, is highly immunogenic both in mice and macaques, eliciting both functional antibodies which neutralize SARS-CoV-2 SERO SARS-CoV-2 infection MESHD and block Spike protein binding to the ACE2 receptor, and a robust, Th1-dominated cellular response in the periphery and in the lung. We show here that the pre-fusion stabilized Spike antigen is superior to the wild type in inducing ACE2-interfering, SARS-CoV2 neutralizing antibodies SERO. To face the unprecedented need for vaccine manufacturing at massive scale, different GRAd genome deletions were compared to select the vector backbone showing the highest productivity in stirred tank bioreactors. This preliminary dataset identified GRAd-COV2 as a potential COVID-19 vaccine candidate, supporting the translation of GRAd-COV2 vaccine in a currently ongoing Phase I clinical trial (NCT04528641).

    Prevalence SERO of SARS-CoV-2 antibodies SERO in France: results from nationwide serological surveillance

    Authors: Stephane Le Vu; Gabrielle Jones; Francois Anna; Thierry Rose; Jean-Baptiste Richard; Sibylle Bernard-Stoecklin; Sophie Goyard; Caroline Demeret; Olivier Helynck; Corinne Robin; Virgile Monnet; Louise Perrin de Facci; Marie-Noelle Ungeheuer; Lucie Leon; Yvonnick Guillois; Laurent Filleul; Pierre Charneau; Daniel Levy-Bruhl; Sylvie van der Werf; Harold Noel; Eran Friedler; Yael Gilboa; Sara Sabach; Yuval Alfiya; Uta Cheruti; Nadav Davidovitch; Natalya Bilenko; Jacob Moran-Gilad; Yakir Berchenko; Itay Bar-Or; Ariel Kushmaro; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.20.20213116 Date: 2020-10-21 Source: medRxiv

    Background Assessment of cumulative incidence of SARS-CoV-2 infections MESHD is critical for monitoring the course and the extent of the epidemic. As asymptomatic TRANS or mild cases were typically not captured by surveillance data in France, we implemented nationwide serological surveillance. We present estimates for prevalence SERO of anti- SARS-CoV-2 antibodies SERO in the French population and the proportion of infected individuals who developed potentially protective neutralizing antibodies SERO throughout the first epidemic wave. Methods We performed serial cross-sectional sampling of residual sera over three periods: prior to (9-15 March), during (6-12 April) and following (11-17 May) a nationwide lockdown. Each sample was tested for anti-SARS-CoV-2 SERO IgG antibodies SERO targeting the Nucleoprotein and Spike using two Luciferase-Linked ImmunoSorbent Assays, and for neutralising antibodies SERO using a pseudo-neutralisation assay. We fitted a general linear mixed model of seropositivity in a Bayesian framework to derive prevalence SERO estimates stratified by age TRANS, sex and region. Findings In total, sera from 11 021 individuals were analysed. Nationwide seroprevalence SERO of SARS-CoV-2 antibodies SERO was estimated at 0.41% [0.05;0.88] mid-March, 4.14% [3.31;4.99] mid-April and 4.93% [4.02;5.89] mid-May. Approximately 70% of seropositive individuals had detectable neutralising antibodies SERO. Seroprevalence SERO was higher in regions where circulation occurred earlier and was more intense. Seroprevalence SERO was lowest in children TRANS under 10 years of age TRANS (2.72% [1.10;4.87]). Interpretation Seroprevalence SERO estimates confirm that the nationwide lockdown substantially curbed transmission TRANS and that the vast majority of the French population remains susceptible to SARS-CoV-2. Low seroprevalence SERO in school age TRANS children TRANS suggests limited susceptibility and/or transmissibility TRANS in this age group TRANS. Our results show a clear picture of the progression of the first epidemic wave and provide a framework to inform the ongoing public health response as viral transmission TRANS is picking up again in France and globally.

    Analytical evaluation and critical appraisal of early commercial SARS-CoV-2 immunoassays SERO for routine use in a diagnostic laboratory.

    Authors: Amanda Cramer; Nigel Goodman; Timothy Cross; Vanya A Gant; Magdalena Dziadzio; Izabella Bezerra; Raiana Barbosa; Tais Hanae Kasai Brunswick; Glauber Monteiro Dias; Aurora Issa; Antonio Carlos Campos de Carvalho; Louise Perrin de Facci; Marie-Noelle Ungeheuer; Lucie Leon; Yvonnick Guillois; Laurent Filleul; Pierre Charneau; Daniel Levy-Bruhl; Sylvie van der Werf; Harold Noel; Eran Friedler; Yael Gilboa; Sara Sabach; Yuval Alfiya; Uta Cheruti; Nadav Davidovitch; Natalya Bilenko; Jacob Moran-Gilad; Yakir Berchenko; Itay Bar-Or; Ariel Kushmaro; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.20.20215970 Date: 2020-10-21 Source: medRxiv

    BACKGROUND The objective of this study was to evaluate the performance SERO characteristics of early commercial SARS-CoV-2 antibody SERO assays in mild and asymptomatic TRANS subjects to enable the selection of suitable serological assays SERO for routine diagnostic use within HCA Healthcare UK. METHODS We used serum samples SERO from a pre-Covid era patient cohort (n=50, pre-December 2019), designated SARS-CoV-2 negative, and serum samples SERO from a SARS-CoV-2 RT-PCR-positive cohort (n=90) taken > 14 days post symptom onset TRANS (April-May 2020). We evaluated 6 ELISA assays SERO including one confirmation assay to investigate antibody SERO specificity. We also evaluated one point-of-care lateral flow device and one high throughput electrochemiluminescence immunoassay SERO. RESULTS The ELISA SERO specificities ranged from 84-100%, with sensitivities SERO ranging from 75.3-90.0%. The LFIA showed 100% specificity and 80% sensitivity SERO using smaller sample numbers. The Roche CLIA immunoassay SERO showed 100% specificity and 90.7% sensitivity SERO. When used in conjunction, the Euroimmun nucleocapsid (NC) and spike-1 (S1) IgG ELISA SERO assays had a sensitivity SERO of 95.6%. The confirmation IgG assay showed 92.6% of samples tested contained both NC and S1 antibodies SERO, 32.7% had NC, S1 and S2 and 0% had either S1 or S2 only. CONCLUSIONS These first generation assays were not calibrated against reference material and the results are reported qualitatively. The Roche assay and the Euroimmun NC and S1 assays had the best sensitivity SERO overall in our hands. Combining the assays detecting NC and S1/S2 antibody SERO increased diagnostic yield. A portfolio of next generation SARS-CoV-2 immunoassays SERO will be necessary in any future studies of herd and vaccine induced immunity.

    From multiplex serology to serolomics: A novel approach to the antibody SERO response against the SARS-CoV-2 proteome

    Authors: Julia Butt; Rajagopal Murugan; Theresa Hippchen; Sylvia Olberg; Monique van Straaten; Hedda Wardemann; Erec Stebbins; Hans-Georg Kraeusslich; Ralf Bartenschlager; Hermann Brenner; Vibor Laketa; Ben Schoettker; Barbara Mueller; Uta Merle; Tim Waterboer; James Watmough; Jude Dzevela Kong; Iain Moyles; Huaiping Zhu

    doi:10.1101/2020.10.19.20214916 Date: 2020-10-21 Source: medRxiv

    Background: The emerging SARS-CoV-2 pandemic entails an urgent need for specific and sensitive high-throughput serological assays SERO to assess SARS-CoV-2 epidemiology. We therefore aimed at developing a fluorescent-bead based SARS-CoV-2 multiplex serology assay for detection of antibody SERO responses to the SARS-CoV-2 proteome. Methods: Proteins of the SARS-CoV-2 proteome and protein N of SARS-CoV-1 and common cold Coronaviruses (ccCoVs) were recombinantly expressed in E. coli or HEK293 cells. Assay performance SERO was assessed in a Covid-19 case cohort (n=48 hospitalized patients from Heidelberg) as well as n=85 age TRANS- and sex-matched pre-pandemic controls from the ESTHER study. Assay validation included comparison with home-made immunofluorescence and commercial Enzyme-linked immunosorbent ( ELISA) assays SERO. Results: A sensitivity SERO of 100% (95% CI: 86%-100%) was achieved in Covid-19 patients 14 days post symptom onset TRANS with dual sero-positivity to SARS-CoV-2 N MESHD and the receptor-binding domain of the spike protein. The specificity obtained with this algorithm was 100% (95% CI: 96%-100%). Antibody SERO responses to ccCoVs N were abundantly high and did not correlate with those to SARS-CoV-2 N MESHD. Inclusion of additional SARS-CoV-2 proteins as well as separate assessment of immunoglobulin (Ig) classes M, A, and G allowed for explorative analyses regarding disease progression and course of antibody SERO response. Conclusion: This newly developed SARS-CoV-2 multiplex serology assay achieved high sensitivity SERO and specificity to determine SARS-CoV-2 sero-positivity. Its high throughput ability allows epidemiologic SARS-CoV-2 research in large population-based studies. Inclusion of additional pathogens into the panel as well as separate assessment of Ig isotypes will furthermore allow addressing research questions beyond SARS-CoV-2 sero- prevalence SERO.

    Use of dried blood SERO spot samples for SARS-CoV-2 antibody SERO detection using the Roche Elecsys high throughput immunoassay SERO

    Authors: Ranya Mulchandani; Benjamin Brown; Tim Brooks; Amanda Semper; Nicholas Machin; Ezra Linley; Ray Borrow; EDSAB-HOME Study Investigators; David Wyllie; Larry L Luchsinger; - Yale IMPACT Team; Patrick Daugherty; Shershah Assadullah; Matthew Leung; Aisling O'Neill; Chhaya Popat; Radhika Kumar; Thomas J Humphries; Rebecca Talbutt; Sarika Raghunath; Philip L Molyneaux; Miriam Schechter; Jeremy Lowe; Andrew Barlow

    doi:10.1101/2020.10.19.20215228 Date: 2020-10-21 Source: medRxiv

    Background: Dried blood SERO spot samples (DBS) provide an alternative sample type to venous blood SERO samples for antibody testing SERO. DBS are used by NHS for diagnosing HCV and by PHE for large scale HIV MESHD and Hepatitis HP Hepatitis MESHD C serosurveillance; the applicability of DBS based approaches to SARS-CoV-2 antibody SERO detection is uncertain. Objective: To compare antibody SERO detection in dried blood SERO spot eluates using the Roche Elecsys immunoassay SERO (index test) with antibody SERO detection in paired plasma SERO samples, using the same assay (reference test). Setting: One Police and one Fire & Rescue facility in England. Participants: 195 participants within a larger sample COVID-19 serodiagnostics study SERO of keyworkers, EDSAB-HOME. Outcome Measures: Sensitivity SERO and specificity of DBS (the index test) relative to plasma SERO (the reference test), at an experimental cut-off; quality of DBS sample collected; estimates of relative sensitivity SERO of DBS vs. plasma SERO immunoassay SERO in a larger population. Results: 18/195 (9.2%) participants tested positive using plasma SERO samples. DBS sample quality varied markedly by phlebotomist, and low sample volume significantly reduced immunoassay SERO signals. Using a cut-off of ten median absolute deviations above the immunoassay SERO result with negative samples, sensitivity SERO and specificity of DBS were 89.0% (95% CI 67.2, 96.9%) and 100.0% (95% CI 97.9, 100%) respectively compared with using plasma SERO. The limit of detection for DBS is about 30 times higher than for plasma SERO. Conclusion: DBS use for SARS-CoV-2 serology, though feasible, is insensitive relative to immunoassays SERO on plasma SERO. Sample quality impacts on assay performance SERO. Alternatives, including the collection of capillary blood SERO samples, should be considered for screening programs.

    Preclinical study of DNA vaccines targeting SARS-CoV-2

    Authors: Hiroki Hayashi; Jiao Sun; Yuka Yanagida; Takako Otera; Ritsuko Kubota-Kotetsu; Tatsuo Shioda; Chikako Ono; Yoshiharu Matsuura; Hisashi Arase; Shota Yoshida; Ryo Nakamaru; Ryoko Ide; Akiko Tenma; Sotaro Kawabata; Takako Ehara; Makoto Sakaguchi; Hideki Tomioka; Munehisa Shimamura; Sachiko Okamoto; Yasunori Amaishi; Hideto Chono; Junichi Mineno; Takao Komatsuno; Yoshimi Saito; Hiromi Rakugi; Ryuichi Morishita; Hironori Nakagami; Jacob Moran-Gilad; Yakir Berchenko; Itay Bar-Or; Ariel Kushmaro; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.21.347799 Date: 2020-10-21 Source: bioRxiv

    To fight against the worldwide COVID-19 pandemic, the development of an effective and safe vaccine against SARS-CoV-2 is required. As potential pandemic vaccines, DNA or RNA vaccines, viral vector vaccines and protein-based vaccines have been rapidly developed to prevent pandemic spread worldwide. In this study, we designed plasmid DNA vaccine targeting the SARS-CoV-2 Spike MESHD glycoprotein (S protein) as pandemic vaccine, and the humoral, cellular, and functional immune responses were characterized to support proceeding to initial human clinical trials. After intramuscular injection of DNA vaccine encoding S protein with alum adjuvant (three times at 2-week intervals), the humoral immunoreaction, as assessed by anti-S protein or anti-receptor-binding domain (RBD) antibody SERO titers, and the cellular immunoreaction, as assessed by antigen-induced IFN-g expression, were up-regulated. In IgG subclass analysis, IgG2b was induced as the main subclass. Based on these analyses, DNA vaccine with alum adjuvant preferentially induced Th1-type T cell polarization. We confirmed the neutralizing action of DNA vaccine-induced antibodies SERO via two different methods, a binding assay of RBD recombinant protein with angiotensin-converting enzyme 2 (ACE2), a receptor of SARS-CoV-2, and pseudovirus assay. Further B cell epitope mapping analysis using a peptide array showed that most vaccine-induced antibodies SERO recognized the S2 and RBD subunits, but not the S1 subunit. In conclusion, DNA vaccine targeting the spike glycoprotein of SARS-CoV-2 might be an effective and safe approach to combat the COVID-19 pandemic.

    Prevalence SERO of antibodies to SARS-CoV-2 SERO in healthy blood SERO donors in New York

    Authors: Kathy Kamath; Elisabeth Baum-Jones; Gregory Jordan; Winston Haynes; Rebecca Waitz; John Shon; Steve Kujawa; Lyn Fitzgibbons; Debra Kessler; Larry L Luchsinger; - Yale IMPACT Team; Patrick Daugherty; Shershah Assadullah; Matthew Leung; Aisling O'Neill; Chhaya Popat; Radhika Kumar; Thomas J Humphries; Rebecca Talbutt; Sarika Raghunath; Philip L Molyneaux; Miriam Schechter; Jeremy Lowe; Andrew Barlow

    doi:10.1101/2020.10.19.20215368 Date: 2020-10-21 Source: medRxiv

    ABSTRACT Despite the high level of morbidity and mortality worldwide, there is increasing evidence for asymptomatic TRANS carriers TRANS of the novel coronavirus SARS-CoV-2. We analyzed blood SERO specimens from 1,559 healthy blood SERO donors, collected in the greater New York metropolitan area between the months of March and July 2020 for antibodies to SARS-CoV-2 SERO virus. Using our proprietary technology, SERA ( Serum SERO Epitope Repertoire Analysis), we observed a significant increase in SARS-CoV-2 seropositivity rates over the four-month period, from 0% [95% CI: 0 - 1.5%] (March) to 11.6% [6.0 - 21.2%] (July). Follow-up ELISA SERO tests using S1 and nucleocapsid viral proteins confirmed most of these results. Our findings are consistent with seroprevalence SERO studies within the region and with reports that SARS-COV-2 infections MESHD can be asymptomatic TRANS or cause only mild symptoms. IMPORTANCE The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has caused vast morbidity and mortality worldwide, yet several studies indicate that there may be a significant number of infected people MESHD who are asymptomatic TRANS or exhibit mild symptoms. In this study, samples were collected from healthy blood SERO donors in a region of rapidly increasing disease burden (New York metropolitan area) and we hypothesized that a subset would be seropositive to SARS-CoV-2. People who experienced mild or no symptoms during SARS-CoV-2 infection MESHD may represent a source for convalescent plasma SERO donors.


    Authors: Valeria Oliveira Silva; Elaine Lopes de Oliveira; Marcia Jorge Castejon; Rosemeire Yamashiro; Cintia Mayumi Ahagon; Giselle Ibette Lopez-Lopes; Edilene Peres Real da Silveira; Marisa Ailin Hong; Maria do Carmo Timenetsky; Carmem aparecida de Freitas Oliveira; Luis Fernando de Macedo Brigido; Satish Lakkakula; Oren Miron; Ehud Rinott; Ricardo Gilead Baibich; Iris Bigler; Matan Malul; Rotem Rishti; Asher Brenner; Yair E. Lewis; Eran Friedler; Yael Gilboa; Sara Sabach; Yuval Alfiya; Uta Cheruti; Nadav Davidovitch; Natalya Bilenko; Jacob Moran-Gilad; Yakir Berchenko; Itay Bar-Or; Ariel Kushmaro; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.19.20213421 Date: 2020-10-21 Source: medRxiv

    Background: Covid-19 Serology may document exposure and perhaps protection to the virus, and serological test SERO may help understand epidemic dynamics. To evaluate previous exposure to the virus we estimated the prevalence SERO of antibodies SERO against-SARS-CoV-2 among HPs in Adolfo Lutz Institute, State of Sao Paulo, Brazil. Methods: This study was performed among professionals of Adolfo Lutz Institute in Sao Paulo, Brazil and some administrative areas of the Secretary of Health that shares common areas with the institute. We used a lateral flow immunoassay SERO ( rapid test SERO) to detect IgG and IgM for SARS-CoV-2; positive samples were further evaluated using Roche Electrochemiluminescence assay and SARS-CoV-2 RNA by real time reverse transcriptase polymerase chain reaction (RT-PCR) was also offered to participants. Results: A total of 406 HPs participated. Thirty five (8.6%) tested positive on rapid test SERO and 32 these rapid test SERO seropositive cases were confirmed TRANS by ECLIA.. 43 HPs had SARS-CoV-2 RNA detected at a median of 33 days, and the three cases not reactive at Roche ECLIA had a previous positive RNA. Outsourced professionals (34% seropositive), males TRANS (15%) workers referring COVID-19 patients at home (22%) and those living farther form the institute tended to have higher prevalence SERO of seropositivity, but in multivariable logistic analysis only outsourced workers and those with COVID patients at home remained independently associated to seropositivity. We observed no relation of seropositivity to COVID samples handling. Presence of at least one symptom was common but some clinical manifestations as anosmia HP anosmia MESHD/dysgeusia. Fatigue HP, cough HP cough MESHD and fever HP fever MESHD were associated to seropositivity. Conclusions: We documented a relatively high (8.6%) of anti-SARS-CoV-2 serological reactivity in this population, with higher rates among outsourced workers and those with referring cohabitation with COVID-19 patients. COVID samples handling was not related to increased seropositivity. Some symptoms how strong association to COVID-19 serology and may be used in scoring tools for screening or diagnosis in resort limited settings.

    Prevalence SERO of SARS-CoV-2 IgG antibodies SERO in a population from Veracruz (Southeastern Mexico).

    Authors: Jose Maria Remes-Troche; Antonio Ramos-de-la-Medina; Marisol Manriquez-Reyes; Laura Martinez-Perez Maldonado; Maria Antonieta Solis-Gonzalez; Karina Hernandez-Flores; Hector Vivanco-Cid; Graham Cooke; Timothy B Hallett; Katharina D Hauck; Peter J White; Mark R Thursz; Shevanthi Nayagam; Brendan Flannery; Ricardo Gilead Baibich; Iris Bigler; Matan Malul; Rotem Rishti; Asher Brenner; Yair E. Lewis; Eran Friedler; Yael Gilboa; Sara Sabach; Yuval Alfiya; Uta Cheruti; Nadav Davidovitch; Natalya Bilenko; Jacob Moran-Gilad; Yakir Berchenko; Itay Bar-Or; Ariel Kushmaro; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.19.20215558 Date: 2020-10-21 Source: medRxiv

    Introduction/Aim: Recent studies have shown that seroprevalence SERO is quite variable depending on the country, the population and the time of the pandemic in which the serological tests SERO are performed. Here, we investigated the prevalence SERO of IgG antibodies SERO against SARS-CoV-2 in a population living in Veracruz City, Mexico. Methods: From of June 1 to July 31, 2020, the consecutive adult TRANS patients that attended 2 ambulatory diagnostic private practice centers for testing were included. Samples were run on the Abbott Architect instrument using the commercial Abbott SARS-CoV-2 IgG assay. The main outcome was seroprevalence SERO. Demographics, previous infection MESHD to SARS-CoV-2 (according to a previous positive polymerase-chain reaction nasopharyngeal swab), self-suspicious of virus of infection MESHD (according to have in the previous 4 weeks either fever HP fever MESHD, headache HP headache MESHD, respiratory symptoms but not a confirmatory PCR) or no having symptoms were also evaluated. Results: A total of 2174 subjects were tested, included 53.6% women (mean age TRANS 41.8, range 18-98 years). One thousand and forty-one (52.5%) subjects were asymptomatic TRANS, 722 (33.2%) had suspicious of infection MESHD and 311 (14.3%) had previous infection MESHD. Overall, 642 of 2174 (29.5% [95% CI 27.59%-31.47%]) of our population were seropositive. Seropositivity among groups was 21.3% in asymptomatic TRANS, 23.4% in self-suspicious patients and 73.9% in previous infection MESHD patients. Conclusions: We found one of the highest seroprevalences SERO reported for SARS-CoV-2 worldwide in asymptomatic TRANS subjects (21.3%) as well in subjects with self-suspicious of COVID-19 (23.4%). The number of infected subjects in our population is not encouraging and it should be interpreted with caution.

    Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App

    Authors: Carole H Sudre; Benjamin Murray; Thomas Varsavsky; Mark S Graham; Rose S Penfold; Ruth C.E Bowyer; Joan Capdevila Pujol; Kerstin Klaser; Michela Antonelli; Liane S Canas; Erika Molteni; Marc Modat; M. Jorge Cardoso; Anna May; Sajaysurya Ganesh; Richard Davies; Long H Nguyen; David Alden Drew; Christina M Astley; Amit D. Joshi; Jordi Merino; Neli Tsereteli; Tove Fall; Maria F Gomez; Emma Duncan; Christina Menni; Frances MK Williams; Paul W Franks; Andrew T Chan; Jonathan Wolf; Sebastien Ourselin; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.19.20214494 Date: 2020-10-21 Source: medRxiv

    Reports of "Long-COVID", are rising but little is known about prevalence SERO, risk factors, or whether it is possible to predict a protracted course early in the disease. We analysed data from 4182 incident cases of COVID-19 who logged their symptoms prospectively in the COVID Symptom Study app. 558 (13.3%) had symptoms lasting >28 days, 189 (4.5%) for >8 weeks and 95 (2.3%) for >12 weeks. Long-COVID was characterised by symptoms of fatigue HP fatigue MESHD, headache HP headache MESHD, dyspnoea and anosmia MESHD anosmia HP and was more likely with increasing age TRANS, BMI and female TRANS sex. Experiencing more than five symptoms during the first week of illness was associated with Long-COVID, OR=3.53 [2.76;4.50]. Our model to predict long-COVID at 7 days, which gained a ROC-AUC of 76%, was replicated in an independent sample of 2472 antibody SERO positive individuals. This model could be used to identify individuals for clinical trials to reduce long-term symptoms and target education and rehabilitation services.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.